title: Oral administration of L-arginine in patients with angina or following myocardial infarction may be protective by increasing plasma superoxide dismutase and total thiols with reduction in serum cholesterol and xanthine oxidase.
abstract: Administration of L-arginine has been shown to control ischemic injury by producing nitric oxide which dilates the vessels and thus maintains proper blood flow to the myocardium. In the present study attempt has been made to determine whether oral administration of L-arginine has any effect on oxidant/ antioxidant homeostasis in ischemic myocardial patients [represented by the patients of acute angina (AA) and acute myocardial infarction (MI)]. L-arginine has antioxidant and antiapoptotic properties, decreases endothelin-1 expression and improves endothelial function, thereby controlling oxidative injury caused during myocardial ischemic syndrome. Effect of L-arginine administration on the status of free radical scavenging enzymes, pro-oxidant enzyme and antioxidants viz. total thiols, carbonyl content and plasma ascorbic acid levels in the patients has been evaluated. We have observed that L-arginine administration (three grams per day for 15 days) resulted in increased activity of free radical scavenging enzyme superoxide dismutase (SOD) and increase in the levels of total thiols (T-SH) and ascorbic acid with concomitant decrease in lipid per-oxidation, carbonyl content, serum cholesterol and the activity of proxidant enzyme, xanthine oxidase (XO). These findings suggest that the supplementation of L-arginine along with regular therapy may be beneficial to the patients of ischemic myocardial syndromes.
authors: Department of Biochemistry, Lucknow University, Lucknow, India.
authors: Pratima
authors: P
authors: Tripathi
authors: M
authors: M
authors: Chandra
authors: Mithilesh K
authors: MK
authors: Misra
mesh_terms: D000208:Acute Disease; D000284:Administration, Oral; D000328:Adult; D000368:Aged; D000787:Angina Pectoris / Q000188:drug therapy*; D001120:Arginine / Q000008:administration & dosage / Q000627:therapeutic use*; D002784:Cholesterol / Q000097:blood*; D019332:Endothelin-1 / Q000378:metabolism; D006801:Humans; D008297:Male; D008875:Middle Aged; D009203:Myocardial Infarction / Q000188:drug therapy*; D013438:Sulfhydryl Compounds / Q000097:blood*; D013482:Superoxide Dismutase / Q000097:blood*; D014969:Xanthine Oxidase / Q000097:blood*
chemical_list: D019332:Endothelin-1; D013438:Sulfhydryl Compounds; D001120:Arginine; D002784:Cholesterol; D013482:Superoxide Dismutase; D014969:Xanthine Oxidase